Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 376-383

  Takemoto, Norihiro ^a   Tada, Mitsuhiro ^a   Hida, Yasuhiro ^a   Asano, Toshimichi ^a   Cheng, Shaoqiang ^a   Kuramae, Tarou ^a   Hamada, Jun Ichi ^a   Miyamoto, Masaki ^a   Kondo, Satoshi ^a   Moriuchi, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Matrix metalloproteinase (MMP); Non small cell lung cancer (NSCLC); Prognosis; Quantitative real time reverse transcriptase polymerase chain reaction (RT PCR); Reversion inducing cysteine rich protein with Kazal motifs (RECK); Surgery

Indexed keywords

CYSTEINE RICH PROTEIN 61; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE INHIBITOR; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; NEOPLASMS, SQUAMOUS CELL; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 35748935561     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.004     Document Type: Article

References (25)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics 2005. CA Cancer. J Clin 55 (2005) 10-30
2. Woessner Jr. J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5 (1991) 2145-2154
3. Pendas A.M., Knauper V., Puente X.S., Llano E., Mattei M.G., Apte S., et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 272 (1997) 4281-4286
4. Kitayama H., Sugimoto Y., Matsuzaki T., Ikawa Y., and Noda M. A ras-related gene with transformation suppressor activity. Cell 56 (1989) 77-84
5. Noda M., Kitayama H., Matsuzaki T., Sugimoto Y., Okayama H., Bassin R.H., et al. Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc Natl Acad Sci USA 86 (1989) 162-166
6. Takahashi C., Akiyama N., Matsuzaki T., Takai S., Kitayama H., and Noda M. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene. Oncogene 12 (1996) 2137-2146
7. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl. Acad Sci USA 95 (1998) 13221-13226
8. Sasahara R.M., Takahashi C., Sogayar M.C., and Noda M. Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Braz J Med Biol Res 32 (1999) 891-895
9. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107 (2001) 789-800
10. Rhee J.S., and Coussens L.M. RECKing MMP function: implications for cancer development. Trends Cell Biol 12 (2002) 209-211
11. Furumoto K., Arii S., Mori A., Furuyama H., Gorrin Rivas M.J., Nakao T., et al. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing cysteine-rich protein with Kazal motifs. Hepatology 33 (2001) 189-195
12. Masui T., Doi R., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 9 (2003) 1779-1784
13. Span P.N., Sweep C.G., Manders P., Beex L.V., Leppert D., and Lindberg R.L. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97 (2003) 2710-2715
14. Takenaka K., Ishikawa S., Kawano Y., Yanagihara K., Miyahara R., Otake Y., et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40 (2004) 1617-1623
15. Takeuchi T., Hisanaga M., Nagao M., Ikeda N., Fujii H., Koyama F., et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10 (2004) 5572-5579
16. van der Jagt M.F., Sweep F.C., Waas E.T., Hendriks T., Ruers T.J., Merry A.H., et al. Correlation of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 237 (2006) 289-297
17. Song S.Y., Son H.J., Nam E., Rhee J.C., and Park C. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 42 (2006) 101-108
18. Travis W.D. Histological typing of lung and pleural tumours. 3rd ed. (1999), Springer-Verlag, Berlin
19. Sobin L.H., and Wittekind C. International union against cancer. TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York
20. Noda M., Oh J., Takahashi R., Kondo S., Kitayama H., and Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22 (2003) 167-175
21. Hsu M.C., Chang H.C., and Hung W.C. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 281 (2006) 4718-4725
22. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., et al. antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
23. Rozic J.G., Chakraborty C., and Lala P.K. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93 (2001) 497-506
24. Liu L.T., Chang H.C., Chiang L.C., and Hung W.C. Induction of RECK by non-steroidal anti-inflammatory drugs in lung cancer cells. Oncogene 21 (2002) 8347-8350
25. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25 (2006) 9-34